Takeda chief woos top Shire investors over £35bn deal
THE chief of the Japanese pharmaceutical giant circling FTSE 100 drugmaker Shire is to fly to the US this week as part of an international charm offensive to persuade investors to back a £35bn takeover bid for its UK rival.
Christophe Weber, the French boss of Takeda, is understood to be lining up meetings with its major shareholders ahead of making a potential offer for Shire. Its top five investors include US-based Blackrock, Capital Group and JP Morgan. City sources told The
Daily Telegraph that Takeda was understood to be considering splitting Shire and selling its neuroscience division in order to help finance the deal.
Concerns have been raised by analysts that Takeda will struggle to fund the takeover.
Analysts said selling Shire’s neuroscience division – including its lucrative portfolio of ADHD drugs – may make sense as the two companies’ units were focused in different areas. Takeda would be left with Shire’s larger and higher margin rare diseases business.
Takeda declined to comment.